JFIFpPhotoshop 3.08BIMT@Can GLP-1 Medications Enhance Health Outcomes in Individuals wit720260701PSCIENMAGUAuthorpCan GLP-1 Medications Enhance Health Outcomes in Individuals with Type 2 Diabetes and Peripheral Artery Disease? Science@https://scienmag.com/can-glp-1-medications-enhance-health-outcom© 2026 Sciencehttps://scienmag.com/In a groundbreaking advancement for the intersection of endocrinology and vascular medicine, recent research has illuminated the multifaceted benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in improving long-term outcomes for patients grappling with both Type 2 diabetes and peripheral artery disease (PAD). Published in the Journal of the American Heart Association, this new evidence […]ScienceMedMedicineMedicine anti-inflammatory effects of GLP,cardiovascular benefits of GLP-1 medications(endothelial function modulation by GLP-1+GLP-1 receptor agonists for type 2 diabetes-hospitalizations reduction in type 2 diabetes)improving glycemic control with GLP-1 RAs+lowering mortality in diabetic PAD patients0managing diabetes-related vascular complications+peripheral artery disease treatment options reducing limb amputations in PAD'vascular health improvement in diabetes&weight loss effects of GLP-1 therapiesC    !'"#%%%),($+!$%$C   $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$"E !1AQq"2aR5rBs#$%3St4Tbc,!12AQ"aBqR ?W;wUٽip֚G>SXѤne(7aNVg;#ڳtmU#I5wpzO*:));i]f!1ozOՅw}ѝ[좷W &#lqw.o~-VӑMw)]",-{]&a>;G|GmKbk]#99j9djq(ij h~@܀z,5o u코,G E$3HKZZ%#K L&i{AZ˯$ F09ps{s GZlB<~ӽոT%)NQ:ji 4ZYzye6c\W\I7%\#5IJ/Mny?wG&ADl 7Cw-UXev jLUs ̈́R:3-7{imyNjKm;%AcxZQMistAN+]?cdU51[z^RgfU Ils)Hl7Bn7uSp=1H?WT'L?}%nr#Ȅ!S; ,zǽAlmt'_ <ZtoG"8"(k3 (ekZ>Ff 94y5ΕC=;\H2L4 ܒx De S=,s㉕1IMOs98\ېUZl,`.VH.QU'a0JZwœS?ı*:IDqn(_M:4S7/i~䵍%R`X ψŒr~[O}%NUs,51ŏ}Askiuz.JS¼jͯUE*+\ۼCbco}KCAmh$?kj^)OA%B`I`727B@Zf ?*N`CK8BRzXqJZyo+CEa)>,rDj+ꤨ 4V՘s`ϑd0T洸[n*:ʷ($v=6678|V _;dR][(;vCi]]⚶rl,BjWT 6qbXh`ї7smuTkƪouӢg)L'B⹸4;Uma]\^\>jҟip>nx7_ܓ:NƺXy9-[? OKT$^K:~Jkgq)*+Ys[Xig)Fʨpֺ_{ 7:S 5r5:~[m|SJ>}=E`#;S{]9i cq͜^g51DѲG5^?9YQI r:=96ŕl>"yȈ ,7Bs< 9;%J/PoPxgl;[f?)>,䉴R8͂:g,/x]Ra<r.ʗͭNڊWRc=j_nh#e+.ڻ3i?iMNTHG֟KU;k%0%0Iw뤍i6/PآSJG,9wp*)^oΌؓ5Კi Y+ؙgkZ{o۞ympQdNqH)36[n^|DXjnPdW9C-οp5P\cf/8Nة1-!! j&{CsX&׶;Q&ةq )Y㱫hxt}_USʮsO3hd~\]nvs7w0Nb#џ -r,y'OYA 1\ qk-lis: }aʁ! q2{ٛ,پB${ķ 9'TZ-6J)D-7U.;@ A-++dliSC]8sy|$8͆eiS*u~THZr֗#&;04;b6+@ԛ"eKvgR\K'i#of $ZrEe`2t;w͡Bݵe}Zt6^:TQ8l-=Zق?iF"~LQU>KHWQ2T1-cI~۽mm) 0ԓ؍5z%`7BM"C}J-Z;/P14 !Q} \\(X-! BX[p@]$AAPl.oBP! 28!H